Clinical trial readout dates for Moderna Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2027.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 1/2 mRNA-1403 Norovirus Acute Gastroenteritis · NCT05992935 | October 2026 Primary data collected |
| Phase 3 mRNA-1345 Respiratory Syncytial Virus · NCT06067230 | July 2026 Primary data collected |
| Phase 2 mRNA-1345 Respiratory Syncytial Virus · NCT06143046 | May 2026 Primary data collected |
| Phase 3 mRNA-1018-H5 Influenza · NCT07496450 | January 2027 Ongoing |
| Phase 3 mRNA-1403 Acute Gastroenteritis; Norovirus Acute Gastroenteritis · NCT06592794 | February 2027 Ongoing |
| Phase 2 mRNA-1647 Cytomegalovirus Infection · NCT05683457 | March 2027 Ongoing |
| Phase 1/2 mRNA-3927 Propionic Acidemia · NCT04159103 | August 2027 Recruiting |
| Phase 2 mRNA-1982 Lyme Disease · NCT07561294 | November 2028 Ongoing |
| Phase 2 mRNA-1195 Multiple Sclerosis · NCT06735248 | January 2029 Recruiting |
| Phase 2 mRNA-1283 SARS-CoV-2 · NCT07808697 | August 2029 Recruiting |
These dates have elapsed; the company may have reported, or guidance may have shifted.
| Phase 1/2 mRNA-3745 Glycogen Storage Disease · NCT05095727 | November 2026 Ongoing |
Moderna Inc. reported $7.98B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-06). It reported net income of $162M for that quarter.
| 8-K Material Agreement — partnership or licensing deal | 2026-11-16 |
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-06 |